Merck/Biomira Lung Cancer Vaccine Phase III To Start Mid-2006 Following Deal
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck KGaA and Biomira will begin Phase III studies of lung cancer vaccine BLP25 in mid-2006, according to Biomira